Stability and Variation of Plasma Concentrations of Isoniazid, Rifampicin and Pyrazinamide

doi:10.19803/j.1672-8629.2019.11.08

Abstract

Abstract: Objective To investigate the stability, regularity and variation of plasma drug concentration of three commonly used first-line anti-tubercular drugs, and to assess and improve the value of therapeutic drug monitoring (TDM) in guiding individualized applications of clinical anti-tubercular drugs. Methods By comparing the deviations of plasma concentrations between two times of testing, we analyzed the stability of plasma concentrations of three of three anti-tubercular drugs - isoniazid, rifampicin and pyrazinamide. Moreover, the extent to which isoniazid, rifampicin and pyrazinamide varied was compared by uniforming and analyzing the data by dividing the deviations of the Results of two-time tests by the average of the paired Results. Results It was found that each drug had a concentration disparity between the two-time testing. However, there was no significant differences between the two lines of data in paired t-test (isoniazid: t=0.924, P=0.363; rifampicin: t=0.054, P=0.957; pyrazinamide: t=1.027, P=0.323). Further analysis revealed that the variation of isoniazid and rifampicin was larger than that of pyrazinamide. Conclusion During individualized treatment based on TDM monitoring, drugs which have large fluctuation in metabolic changes and intracorporal exposure levels, such as isoniazid and rifampicin, need to be detected more than once as actually required.

Key words: rational clinical drug use, therapeutic drug monitoring, anti-tubercular drugs, pharmacokinetics

CLC Number:

R917

ZHOU Jun, LIU Yuan, LV Xiaohui, ZHAO Yuan, XIONG Chaogang, LEI Qian, WANG Hao. Stability and Variation of Plasma Concentrations of Isoniazid, Rifampicin and Pyrazinamide[J]. Chinese Journal of Pharmacovigilance, 2019, 16(11): 678-682.

References

[1] Krieger C A, Cunningham J L, Grothe K B, et al.Comparisonof Bioavailability of Single-Dose Extended-Release VenlafaxineCapsules in Obese Patients Before and After Gastric BypassSurgery[J]. Pharmacotherapy, 2017, 37(11): 1374-1382.
[2] 颜彪华,李兵. 结核合并肝损伤对抗结核药物血药浓度的影响[J]. 当代医学, 2013, 19(10): 30-31.
[3] 肖和平. 抗结核药物的合理使用是控制耐药结核病流行的基石[J]. 中华结核和呼吸杂志, 2014, 37(10): 723-724.
[4] Lv X Z, Tang S W, Xia Y Y, et al.Adverse reactions due todirectly observed treatment strategy therapy in Chinesetuberculosis patients: a prospective study[J]. PLoS One,2013, 8(6): e65037.
[5] Weiner M, Burman W, Vernon A, et al.Low isoniazid concentrationsand outcome of tuberculosis treatment with once-weeklyisoniazid and rifapentine[J]. Am J Resp Crit Care, 2003,167(10): 1341-1347.
[6] Dheda K, Gumbo T, Gandhi N R, et al.Global control oftuberculosis: from extensively drug-resistant to untreatabletuberculosis[J]. Lancet Respir Med, 2014, 2(4): 321-338.
[7] Jing Y, Zhu L Q, Yang J W, et al.Population pharmacokineticsof rifampicin in Chinese patients with pulmonary tuberculosis[J]. J Clin Pharmacol, 2016, 56(5): 622-627.
[8] 赵冠仁,彭明丽,申健,等. HPLC-MS/MS方法同时检测人血浆中异烟肼、利福平、乙胺丁醇、吡嗪酰胺和左氧氟沙星的浓度[J]. 中国药物应用与监测, 2015, 12(1):16-19.
[9] 魏香兰,方如塘,师延峰,等. 抗结核药物的血药浓度监测结果分析[J]. 中国医院药学杂志, 2015, 35(21): 1918-1921.
[10] 赵嫄,雷倩,党丽云,等. 抗结核药物血药浓度监测工作的思考和展望[J]. 中国防痨杂志, 2017, 39(11): 1228-1232.
[11] World Health Organization.Global Tuberculosis Control:WHO Report 2016[R]. Geneva: World Health Organization,2016.
[12] Choi R, Jeong B H, Koh W J, et al.Recommendations forOptimizing Tuberculosis Treatment: Therapeutic Drug Monitoring,Pharmacogenetics, and Nutritional Status Considerations[J].Ann Lab Med, 2017, 37(2): 97-107.
[13] Alsultan A, Peloquin C A.Therapeutic drug monitoring in thetreatment of tuberculosis: an update[J]. Drugs, 2014, 74(8):839-854.
[14] 汪复, 张婴元. 实用抗感染治疗学[M]. 2版. 北京:人民卫生出版社, 2013:104-109.
[15] Devaleenal D B, Ramachandran G, Swaminathan S.Thechallenges of pharmacokinetic variability of first-line anti-TB drugs[J]. Expert Rev Clin Pharmacol, 2017, 10(1): 47-58.
[16] 周俊,吕小会,刘元,等. 三种抗结核药物血药浓度在个体及药物间的差异研究[J]. 中国防痨杂志, 2017, 39(5):482-487.
[17] Srinivas N R.Pharmacokinetic Interaction of Rifampicinwith Oral Versus Intravenous Anticancer Drugs: Challenges,Dilemmas and Paradoxical Effects Due to Multiple Mechanisms[J]. Drugs R D, 2016, 16(2): 141-148.
[18] Jiao Y, Kim T H, Tao X, et al.First population pharmacokineticanalysis showing increased quinolone metabolite formationand clearance in patients with cystic fibrosis compared tohealthy volunteers[J]. Eur J Pharm Sci, 2018, 123(1): 416-428.
[19] Wang P C, Pradhan K, Zhong X B, et al.Isoniazid metabolismand hepatotoxicity[J]. Acta Pharm Sin B, 2016, 6(5): 384-392.
[20] 吴雪琼,张宗德,乐军. 分枝杆菌分子生物学[M]. 1版.北京:人民军医出版社, 2010:124-125.
[21] Mota L, Al-Efraij K, Campbell J R, et al.Therapeutic drugmonitoring in anti-tuberculosis treatment: a systematic reviewand meta-analysis[J]. Int J Tuberc Lung Dis, 2016, 20(6): 819-826.